EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy

Jiri Bonaventura iD, Ethan J Rowin iD, Raymond H Chan iD, Michael T Chin iD, Veronika Puchnerova iD, Eva Polakova iD, Milan Macek iD, Pavel Votypka iD, Rebecca Batorsky iD, Gayani Perera iD, Benjamin Koethe iD, Josef Veselka und 2 weitere

Journal of the American Heart Association · 21.05.2024 · 13 (10)

DOI: 10.1161/jaha.123.033565 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 21.05.2024. Verfasst von Jiri Bonaventura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Genotype. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events.

Conclusions

In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicGenotypeHumansMaleFemaleMiddle AgedAdultMutationPhenotypeDisease ProgressionRisk FactorsGenetic Predisposition to DiseaseAgedGenetic TestingPrognosisTime FactorsHeart FailureDeath, Sudden, CardiacHeart Transplantation

Stichwörter der Autor:innen

genotypehypertrophic cardiomyopathymortalityoutcomessudden death

Autor:innen und Institutionen

  • Department of Cardiology, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic.
  • Hypertrophic Cardiomyopathy Center Lahey Hospital and Medical Center Burlington MA USA.
  • Division of Cardiology, Peter Munk Cardiac Centre Toronto General Hospital, University Health Network Ontario Canada.
  • Molecular Cardiology Research Institute Tufts Medical Center Boston MA USA.
  • Department of Biology and Medical Genetics, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic.
  • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center Boston MA USA.

ORCID-Profile: Jiri Bonaventura, Ethan J Rowin, Raymond H Chan, Michael T Chin, Veronika Puchnerova, Eva Polakova, Milan Macek, Pavel Votypka, Rebecca Batorsky, Gayani Perera, Benjamin Koethe, Barry J Maron, Martin S Maron

Zitieren

APA

Bonaventura, J., Rowin, E. J., Chan, R. H., Chin, M. T., Puchnerova, V., Polakova, E., Macek, M., Votypka, P., Batorsky, R., Perera, G., Koethe, B., Veselka, J., Maron, B. J., & Maron, M. S. (2024). Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 13(10). https://doi.org/10.1161/jaha.123.033565

Vancouver

Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, et al. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2024;13(10). doi:10.1161/jaha.123.033565

BibTeX
@article{Bonaventura2024,
  author = {Bonaventura, Jiri and Rowin, Ethan J and Chan, Raymond H and Chin, Michael T and Puchnerova, Veronika and Polakova, Eva and Macek, Milan and Votypka, Pavel and Batorsky, Rebecca and Perera, Gayani and Koethe, Benjamin and Veselka, Josef and Maron, Barry J and Maron, Martin S},
  title = {Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {10},
  doi = {10.1161/jaha.123.033565}
}
Kostenlos starten →